4th Quarter - Report

TEMPUS LABS INC for TEMPUS LABS INC

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$90,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report (this page) Jan 20, 2023 $90,000 Replaced
4th Quarter - Amendment Apr 20, 2023 $90,000 Replaced
4th Quarter - Amendment May 3, 2023 $80,000 Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

VALID Act of 2021 (HR 4128/S.2209); Issues related to proposals on reauthorization of the FDA drug and device user fee programs within Omnibus Bill (H.R. 2617 ); Issues related to data privacy and security House legislation (H.R. 8152).

LobbyistCovered position, as disclosed
JENNIFER MALLARD —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2617 (117th), S. 2209 (117th), H.R. 4128 (117th), H.R. 8152 (117th)

Medicare/Medicaid MMM

Issues related to cancer diagnostic testing; Medicare coverage of molecular and advanced genomic testing tests; Precision medicine; Health care issues related to data privacy and security House legislation (H.R. 8152).

LobbyistCovered position, as disclosed
JENNIFER MALLARD —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 8152 (117th)

Science/Technology SCI

Data Privacy(H.R. 8152).; Artificial Intelligence/Machine Learning in healthcare. Increasing multi-modal data in medical research and innovation. Advancing acceptance of Real World Data and Real World Evidence. Diversity of clinical trials.

LobbyistCovered position, as disclosed
JENNIFER MALLARD —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 8152 (117th)

Medical/Disease Research/Clinical Labs MED

Access and reimbursement to advanced genomic testing for cancer; Providing an appropriate regulatory model for advanced genomic cancer testing; The VALID Act (HR 4128 and S 2209) and Omnibus legislation (H.R. 2617). Increasing overall access to and diversity of clinical trials. Advancing acceptance of Real World Data and Real World Evidence.

LobbyistCovered position, as disclosed
JENNIFER MALLARD —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2617 (117th), H.R. 4128 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.